



c) Primer sets sequences used for amplification of E6 and E7 oncogenes.

Primer	Fwd. Sequence	Rev. Sequence	Product length
E6 HPV16	5' CAG AGC TGC AAA CAA CTA TAC 3'	5' AGT GGC TTT TGA CAG TTA ATA C 3'	280 bp
E6 HPV18	5' GCG ACC CTA CAA GCT ACC TGA T 3'	5' GCA CCG CAG GCA CCT TAT TA 3'	298 bp
E7 HPV16	5' GAC AAG CAG AAC CGG ACA G 3'	5' ATT CCT AGT GTG CCC ATT AAC A 3'	139 bp
E7 HPV18	5' TGT CAC GAG CAA TTA AGC GAC T 3'	5' CAC ACA AAG GAC AGG GTG TTC A 3'	279 bp

Figure S1. Validation of E6/E7 expression on HaCaT-transduced cell models. **a)** The graphs shown the amplification curves and CPs derived from real-time-PCR utilizing specific primers for *E6* and *E7* oncogenes from HPV 16 and 18. Pure plasmid LVX with *E6/E7* of HPV 16 and 18 were included as positive controls, and HaCaT parental cells were also included. **b)** Electrophoresis on 2% agarose gels were addressed to demonstrate the presence of the amplicon; we expected the following lengths: *E6* HPV16 = 280 bp, *E6* HPV18 = 298 bp, *E7* HPV16 = 139 bp, and *E7* HPV18 = 279 bp. Positive controls: Pure plasmids LVX with *E6/E7* of HPV 16 or 18; Negative controls: HaCaT and HaCaT pLVX. **c)** Sequences used to amplify *E6* or *E7* from HPV16 or 18.

Supplementary Table S1. Primer sets sequences used in qPCR.

Primer	Fwd. Sequence	Rev. Sequence	Product length	Annealing temp.
<i>CCL2</i>	5' GCA GCA AGT GTC CCA A 3'	5' CCC AAG TCT CTG TAT CTA AAA 3'	337 bp	54°C
<i>CCL28</i>	5' AGC TGT TGC ACG GAG GTT T 3'	5' TTC TTG GCA GCT TGC ACT TTC 3'	191bp	60°C
<i>CXCL1</i>	5' TCA AGA ATG GGC GGA AAG 3'	5' CTT CTC CTA AGC GAT GCT CAA 3'	231 bp	58°C
<i>CXCL2</i>	5' GCT TGT CTC AAC CCC GCA 3'	5' CAC ATT AGG CGC AAT CCA GGT 3'	192 bp	60°C
<i>CXCL3</i>	5' GGG AGC ACC AAC TGA C 3'	5' GAA CCC TCG TAA GAA ATA GTC 3'	168 bp	56°C
<i>CXCL6</i>	5' GTC TGG ACC CGG AAG C 3'	5' CCC CAC ACT CTT CAA AGT GG 3'	219 bp	60°C
<i>CXCL8</i>	5' GTG CAG AGG GTT GTG GA 3'	5' ACC AGG AAT CTT GTA TTG CAT 3'	179 bp	56°C
<i>CXCL10</i>	5' GGC CAT CAA GAA TTT ACT GA 3'	5' CAT TAT AGT GCC AGG GTA GAG 3'	292 bp	54°C
<i>CXCL11</i>	5' AGT GAA AGT GGC AGA TAT TG 3'	5' CTT TTC CAG GAC TTC ATA TGT 3'	200 bp	56°C
<i>RPLP0</i>	5' CCT CAT ATC CGG GGG AAT GTG 3'	5' GCA GCA GCT GGC ACC TTA TTG 3'	95 bp	58°C
<i>RPS18</i>	5' CGA TGG GCG GCG GAA AA 3'	5' CAG TCG CTC CAG GTC TTC ACG G 3'	283 bp	58°C

Supplementary Table S2. Summary of all analyses performed.

Chemokine	¹ Cervical Cancer-derived cell lines (RNAseq)			¹ HaCaT-transduced cell models (RNAseq)		² HaCaT-transduced cell models (2-ΔΔCp)		¹ Expression profile of CESC biopsies from TCGA (RNAseq)	³ Overall Survival Analysis (upregulation / prognosis)
	SiHa	HeLa	C33A	E6/E7 HPV16	E6/E7 HPV18	E6/E7 HPV16	E6/E7 HPV16		
<i>CCL2</i>	▼ -5.13	▼ -3.93	▼ -11.03	▲ 4.62	▲ 3.94	▲ 2.95	▲ 3.03	NS	NS
<i>CCL28</i>	▲ 1.66	▼ -4.99	▼ -5.54	▲ 1.48	▲ 4.28	▲ 2.45	▲ 6.94	▲ 0.69	NS
<i>CXCL1</i>	▼ -5.32	▼ -9.73	▼ -8.24	▲ 3.54	▲ 3.62	▼ -0.18	▲ 1.81	▲ 4.84	Worse
<i>CXCL2</i>	▲ 5.14	▲ 5.30	NS	▲ 2.73	▲ 4.06	▲ 3.82	▲ 3.64	NS	Worse
<i>CXCL3</i>	▲ 3.13	▲ 3.43	NS	NS	▲ 4.75	▲ 4.01	▲ 6.19	▲ 2.41	Worse
<i>CXCL6</i>	▼ -8.09	▼ -7.89	▼ -8.85	▲ 3.02	▲ 2.30	▲ 4.07	▲ 3.26	▲ 2.14	Worse
<i>CXCL8</i>	▼ -3.21	▼ -2.29	▼ -9.66	▲ 1.18	▲ 1.74	▲ 0.85	▲ 3.01	▲ 5.22	Worse
<i>CXCL10</i>	▲ 3.62	▲ 5.05	NS	▲ 4.72	▲ 6.42	▲ 3.99	▲ 5.58	▲ 5.72	Better
<i>CXCL11</i>	▲ 4.36	▲ 3.82	NS	NS	▲ 2.55	▲ 2.42	▲ 2.50	▲ 3.94	Worse

* The table summarizes the results of each analysis executed in the present study. ¹The Differential Expression Analysis was performed on Cervical Cancer-derived cell lines, HaCaT-transduced cell models, and CESC biopsies from the TCGA Database. ²For the Relative Expression Analysis on HaCaT-transduced cell models, to normalize the expression data, the *RPS18* and *RPLP0* were taken as reference genes. The data displayed are the means of the two replicates of each reference gene. ³Overall survival data correlates the upregulation of the chemokine panel with the patient's prognosis. All the resulting outputs from the Differential Expression Analysis (RNAseq) and the Relative Expression (2-ΔΔCp) are shown as Log2 Fold-Change. ▲ Upregulation; ▼ Downregulation; (NS) Non-significant.